NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Metabolic Experimental Medicine > Achieving Type 2 diabetes treatment targets would improve health and reduce healthcare costs

Achieving Type 2 diabetes treatment targets would improve health and reduce healthcare costs

8 August 2019 · Listed under Metabolic Experimental Medicine, Other News, Translational Data Science

Improvements in health and reductions in healthcare costs could be achieved if blood glucose, blood pressure and cholesterol treatment targets were met.

Researchers from the Nuffield Department of Population Health, University of Oxford, assessed the long-term impact of achieving treatment targets for Type 2 diabetes on diabetes-related complications, life expectancy, and healthcare costs. The study, published in Diabetes, Obesity and Metabolism, was supported by the NIHR Oxford Biomedical Research Centre and funded by Diabetes UK.

Diabetes affects 9% of the UK adult population, with Type 2 diabetes accounting for approximately 90% of these cases and 5.4 million patients in the UK. Type 2 diabetes is associated with increased risk of complications such as heart disease or stroke that may result in death or severely impair quality of life. An estimated £10 billion, approximately 10% of the NHS budget, is spent on diabetes annually; 80% of this cost is for treatment of diabetes complications. GP practices are encouraged to achieve defined treatment targets for blood glucose, blood pressure and cholesterol.

Mi Jun Keng, a researcher at the Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, and the lead author of the paper, said, “Our study found that meeting more treatment targets was associated with lower risk of a range of diabetes-related complications. Patients would live on average seven months more for each additional treatment target achieved.”

The National Diabetes Audit, which measures the effectiveness of diabetes healthcare, has recently reported improvements in achieving defined treatment targets for blood glucose, blood pressure, and cholesterol among people with Type 2 diabetes. However, the percentage of patients who achieve all three targets is relatively low, ranging from 27% to 54% across groups of GP practices in England and Wales.

Dr Apostolos Tsiachristas, co-author of the paper, added, “Meeting all three treatment targets reduces the costs to the NHS of treating complications by about £1000 per patient. This could lead to substantial savings to the NHS considering the high and increasing prevalence of Type 2 diabetes in England and Wales.”

Professor Borislava Mihaylova, the senior author of the paper noted, “Our study shows that if the 10% lowest performing GP practices (with about a quarter of their patients meeting the targets) were to reach the target levels achieved by the top 10% performing GP practices (with about half of patients meeting the targets), they would realise an average gain of 30 years of life for every 100 patients or 3.6 months per patient. These benefits would more than double if they could get all their patients to meet all three treatment targets.

“There have been many improvements in diabetes care, but we still need to do more to make sure that targets are met consistently. This research provides important information that healthcare commissioners can use to help implement appropriate improvement programmes and ultimately improve the quality of life of patients. We hope that it will also encourage those with Type 2 diabetes to work with their GPs to achieve the targets that are most appropriate to them.”

← International students learn about Oxford’s neuroscience and diabetes research
Future life sciences leaders immerse themselves in Oxford collaborations →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre